"The BRG mouse has appeared in an increasing number of papers from researchers worldwide. CIEA has been distributing limited quantities of this model to academic scientists upon request, but demand has grown in the past few years. To facilitate easy, fast access to this increasingly important mouse model, CIEA sought a commercial partner to scale up production and distribution. CIEA appointed In-Vivo Science Inc. (IVS) as its licensing liaison and worked with IVS to grant commercialization rights for the BRG mouse to Taconic," said Ryuta Nomura, Executive Board, CIEA.
The BRG mouse will be produced at one of Taconic's US breeding facilities for distribution within a licensed territory including the United States, Canada and Europe. The BRG mouse adds to Taconic's portfolio of immunodeficient mice and rats, which is the most comprehensive in the industry. In particular, the BRG mouse will complement the NOG mouse, another super immunodeficient mouse developed at CIEA and distributed by Taconic.
"Taconic is pleased to add another valuable immunodeficient model to its portfolio. The usefulness of the BRG mouse for humanization studies significantly enhances Taconic's current strategic focus on providing researchers with more predictive in vivo models carrying human genes and/or cells," said Todd Little, President and Chief Executive Officer of Taconic. The BRG mouse will be produced by CIEA and supplied by IVS within Japan and other Asian countries. To ensure consistent performance between BRG mice produced across multiple sites worldwide, CIEA and Taconic will work closely together on genetic harmonization and other quality measures. These quality processes are particularly important to support large pharmaceutical companies with multiple sites throughout the world, which require supply of consistent animals to reduce potential variation in research results.
The Central Institute for Experimental Animals (CIEA) was established in 1952. The CIEA have nurtured the technological basis of medical treatment / new drug development, and has contributed human health and welfare. The CIEA seeks to create new technologies such as: 1) Development of quality humanized animals with a stable reproduction level, and 2) Research of human diseases and clarification of their causes through the use of laboratory animals as live measurement standards. Learn more about CIEA.
About In-Vivo Science Inc.
In-Vivo Science provides high quality products and services to contribute human welfare and health. Especially In-Vivo Science has a mission to introduce in vivo experimentation system discovered/developed by CIEA. Learn more by visiting http://www.invivoscience.com/International/iIndex.htm.
Taconic is a leading provider of life sciences solutions to researchers worldwide, offering innovative lab animal models and scientific services that facilitate in vivo studies and advance drug discovery. Taconic's wide range of advanced solutions include custom model design, generation and production, off-the-shelf model repositories, contract research, custom breeding, genetic monitoring, and health testing. Headquartered in New York's Hudson River Valley, Taconic operates seven breeding facilities and three service laboratories in the U.S. and Europe and maintains a staff of over 750 scientific specialists committed to technological innovation.